MX2009012316A - Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12. - Google Patents

Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12.

Info

Publication number
MX2009012316A
MX2009012316A MX2009012316A MX2009012316A MX2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A
Authority
MX
Mexico
Prior art keywords
methods
gprl2
hippocampal
performance
gpr12
Prior art date
Application number
MX2009012316A
Other languages
English (en)
Spanish (es)
Inventor
Timothy P Tully
Roderick E M Scott
Marco Peters
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of MX2009012316A publication Critical patent/MX2009012316A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2009012316A 2007-05-15 2008-05-15 Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12. MX2009012316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93816307P 2007-05-15 2007-05-15
PCT/US2008/063804 WO2008144453A1 (en) 2007-05-15 2008-05-15 Methods of treating cognitive disorders by inhibition of gpr12

Publications (1)

Publication Number Publication Date
MX2009012316A true MX2009012316A (es) 2009-12-03

Family

ID=40122145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012316A MX2009012316A (es) 2007-05-15 2008-05-15 Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12.

Country Status (11)

Country Link
US (2) US7968524B2 (enExample)
EP (1) EP2162137B1 (enExample)
JP (1) JP2010527375A (enExample)
KR (1) KR20100029079A (enExample)
CN (1) CN101808647A (enExample)
AU (1) AU2008254905A1 (enExample)
BR (1) BRPI0811625A2 (enExample)
CA (1) CA2684920A1 (enExample)
IL (1) IL202091A0 (enExample)
MX (1) MX2009012316A (enExample)
WO (1) WO2008144453A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2595720C2 (ru) 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
BR102022009685A2 (pt) * 2022-05-18 2023-11-28 Fundação Oswaldo Cruz Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6045094A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Drug composition containing nucleic acid copolymer
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20060247194A1 (en) 2000-08-30 2006-11-02 Sirna Therapeutics , Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
EP1662862A1 (en) * 2003-09-19 2006-06-07 Paradigm Therapeutics Limited Receptor
SI1745295T1 (sl) * 2004-04-20 2011-01-31 Galapagos Nv Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta

Also Published As

Publication number Publication date
CA2684920A1 (en) 2008-11-27
EP2162137B1 (en) 2016-11-23
US20090022667A1 (en) 2009-01-22
KR20100029079A (ko) 2010-03-15
BRPI0811625A2 (pt) 2014-11-11
JP2010527375A (ja) 2010-08-12
AU2008254905A1 (en) 2008-11-27
WO2008144453A1 (en) 2008-11-27
IL202091A0 (en) 2010-06-16
EP2162137A1 (en) 2010-03-17
WO2008144453A9 (en) 2010-03-18
EP2162137A4 (en) 2011-06-08
CN101808647A (zh) 2010-08-18
US20110281936A1 (en) 2011-11-17
US7968524B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
WO2007071448A3 (en) Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
MX2020011792A (es) Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer.
MX2009012906A (es) Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2009064920A3 (en) Compounds and methods for modulating protein expression
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
SG169988A1 (en) Rnai inhibition of alpha-enac expression
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MX2009012421A (es) Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
EP2509590A4 (en) HISTON ACETYL TRANSFERASE ACTIVATORS AND USES THEREOF
GEP20125586B (en) Novel method for synthesis of (7-methoxy-l-naphthyl)-acetonitrile and application thereof in synthesis of agomelatine
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
TW200806297A (en) Methods for treating cognitive and other disorders
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
MX2012001999A (es) Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.
WO2006133107A3 (en) Specific binding sites in collagen for integrins and use thereof
WO2008008472A3 (en) Methods and compositions for modulating synapse formation
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
EP1551855A4 (en) ALTERATION OF THE MEMORY BY MODIFYING THE FUNCTION OF STAUFEN
WO2006122090A3 (en) Screening assays for compounds regulating dj-i expression